Of Texas/Texas Am I. University Sells 20,315 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock

Aileron Therapeutics, Inc. (NASDAQ:ALRN) major shareholder Of Texas/Texas Am I. University sold 20,315 shares of Aileron Therapeutics stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the transaction, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aileron Therapeutics Stock Down 8.6 %

Shares of NASDAQ ALRN opened at $4.16 on Thursday. The firm has a market cap of $70.60 million, a price-to-earnings ratio of -1.23 and a beta of 2.22. The company’s 50-day simple moving average is $5.43 and its 200-day simple moving average is $3.82. Aileron Therapeutics, Inc. has a 52-week low of $1.01 and a 52-week high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. Equities research analysts anticipate that Aileron Therapeutics, Inc. will post -0.62 EPS for the current fiscal year.

Institutional Trading of Aileron Therapeutics

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp bought a new position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned about 0.34% of Aileron Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH increased their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, April 18th.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.